載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$1.23
−US$0.06 · -4.65%
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
收盤時
US$1.23
−US$0.06 · -4.65%
盤後
US$1.24
+US$0.01 · +0.81%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
日內區間
目前US$1.23
52週區間
目前US$1.23
盤中時間採用ET。市場資料可能有所延遲。
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
日內區間
目前US$1.23
52週區間
目前US$1.23
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.63億 USD | 4.82億 USD | 4.33億 USD | 4.51億 USD | 4.67億 USD |
| 銷貨成本 | 1.38億 USD | 1.16億 USD | 1.06億 USD | 1.05億 USD | 1.14億 USD |
| 毛利 | 4.26億 USD | 3.66億 USD | 3.27億 USD | 3.46億 USD | 3.53億 USD |
| 研究與開發 | 4454.2萬 USD | 5027.1萬 USD | 4438萬 USD | 3976.2萬 USD | 3074.2萬 USD |
| 銷售、一般及管理費用 | 3.26億 USD | 2.95億 USD | 2.7億 USD | 2.84億 USD | 2.5億 USD |
| 營業費用 | 3.7億 USD | 3.68億 USD | 3.14億 USD | 3.24億 USD | 2.81億 USD |
| 利息收入 | 228.1萬 USD | — | — | — | — |
| 利息支出 | — | 154.4萬 USD | 219萬 USD | 200.9萬 USD | 723.6萬 USD |
| 折舊和攤銷 | 2693.8萬 USD | 1702.6萬 USD | 2344.9萬 USD | 1803.1萬 USD | 1667.6萬 USD |
| 營業利益 | 5586.9萬 USD | −128.3萬 USD | 1252.5萬 USD | 2230.4萬 USD | 7221.8萬 USD |
| 淨利 | 3703.2萬 USD | 86.1萬 USD | 494.5萬 USD | 1553.2萬 USD | 9420.2萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.50
上漲空間 103.25%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI342.53萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM235.91萬0.00%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF152.85萬0.00%954億 USD0.05%US$233.52-0.63%
Dimensional - US Targeted Value ETFDFAT73.06萬0.00%301.22億 USD0.33%US$67.42+0.22%
Vanguard Russell 2000 ETFVTWO68.15萬0.00%180億 USD0.06%US$112.27-0.35%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV60.5萬0.00%268.09億 USD0.33%US$37.98+0.08%
Schwab U.S. Small-Cap ETFSCHA51.58萬0.00%218.24億 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT37.98萬0.00%220億 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATVanguard Russell 2000 ETFVTWOU.S. Small Cap Value Portfolio ETF Class SharesDFSVSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
